NCT03344692 (EUTERPE) is a Phase 3 clinical trial of Alirocumab in Type2 Diabetes, sponsored by Nantes University Hospital.

Who is sponsoring NCT03344692?

NCT03344692 is sponsored by Nantes University Hospital.

What drugs are being tested in NCT03344692?

Interventions in NCT03344692: Alirocumab, Placebo.

What condition does NCT03344692 study?

NCT03344692 studies Type2 Diabetes.

Is NCT03344692 still recruiting?

NCT03344692 is currently completed. Last updated 27 September 2022.

Last reviewed 2022-09-27 · How we verify

NCT03344692: EUTERPE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes

Completed Phase 3 Last updated 27 September 2022

What this trial tests

Phase 3 trial testing Alirocumab in Type2 Diabetes in 22 participants. Completed in 28 April 2022.

Timeline

12 February 2019

Primary endpoint
28 April 2022

28 April 2022

Quick facts

Lead sponsor	Nantes University Hospital
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	treatment
Enrollment	22
Start date	12 February 2019
Primary completion	28 April 2022
Estimated completion	28 April 2022
Sites	1 location across France

Drugs / interventions tested

Alirocumab (ALIROCUMAB) — full drug profile →
Placebo

Conditions studied

Type2 Diabetes — all drugs for Type2 Diabetes →

Sponsor

Nantes University Hospital

Who can join

Adults 18 to 75, male only, with Type2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged over the past decade as a post-transcriptional regulator of the LDL receptor (LDL-R). PCSK9 acts as an endogenous natural inhibitor of the LDL-R pathway. Monoclonal antibodies (mAb) directed against PCSK9, such as Alirocumab, are the most common method of PCSK9 inhibition. The goal of the present study is to assess, in the context of type 2 diabetes, a situation associated with an increased post-prandial hyperlipemia, whether PCSK9 inhibition with Alirocumab affects postprandial intestinal lipoprotein metabolism.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Alternative Routes of Administration for Therapeutic Antibodies-State of the Art.
Pitiot A, Heuzé-Vourc'h N, Sécher T. · · 2022 · cited 45× · PMID 36134952 · DOI 10.3390/antib11030056
Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update.
Kaddoura R, Orabi B, Salam AM. · · 2020 · cited 18× · PMID 32939318 · DOI 10.1080/21556660.2020.1801452

Verify or expand the search:

Other trials of Alirocumab

Trials testing the same drug.

NCT07477704 — A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemi · Phase 2 · not yet recruiting
NCT06858332 — Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia · recruiting
NCT06385262 — TOP 2301: Neoadjuvant Chemo for NSCLC · Phase 2 · suspended
NCT06080256 — Extra Alirocumab in Addition to Statin Therapy in Asymptomatic Intracranial Atherosclerotic Stenosis (EAST-aICAS) · Phase 3 · unknown
NCT06083961 — The Effect of Early Administration of PCSK9 Inhibitor to Acute Ischemic Stroke Patients Associated With Atherosclerosis · Phase 4 · not yet recruiting

Other recruiting trials for Type2 Diabetes

Currently open trials in the same condition.

NCT05277558 — Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D) · recruiting
NCT05015283 — Efficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes Remission · NA · recruiting
NCT05006508 — Prevention With the Health and Lifestyle Tool · NA · active not recruiting
NCT04717050 — Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity · NA · active not recruiting
NCT05220917 — Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study · active not recruiting

Other Nantes University Hospital trials

Trials by the same sponsor.

NCT07278661 — Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. · Phase 2 · recruiting
NCT06681363 — Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelod · not yet recruiting
NCT07467382 — GOAT (Gait Observation of Achilles Tendon) · not yet recruiting
NCT07490379 — Comparison of the Efficacy of Transcranial Direct Current Stimulation at Home Versus in Hospital Settings in Patients Wi · NA · not yet recruiting
NCT07423481 — Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03344692 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nantes University Hospital
Last refreshed: 27 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03344692.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing